Transforming drug discovery and target validation from traditional to digital
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients
Excision BioTherapeutics, Inc., is a biotechnology company developing CRISPR-based therapies to cure viral infectious diseases.
Excision is focused on improving the lives of chronically ill patients by eliminating viral genomes from infected individuals. By using CRISPR in unique ways, the company has already demonstrated the first functional cure for HIV in animals.
Excision’s cutting edge CRISPR gene therapy platform is built on technology licensed from the Doudna Lab at UC Berkeley and the Khalili Lab at Temple University.
Tops News & Media Coverage
A Bold Effort to Cure HIV—Using Crispr
Excision BioTherapeutics & Guide RNA
S.F. biotech inches closer to potential HIV cure with key move by FDA
Dual CRISPR therapy plus long-acting ART eliminates HIV in mice
Gene-editing companies are growing thanks to fast-paced science, even as biotech faces a downturn